使用循环肿瘤细胞表面生物标志物进行实时治疗反应监测
Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells.
摘要(中文译文)
循环肿瘤细胞（CTC）从原发肿瘤脱落到血液中，并代表了用于监测癌症进展的动态分子生物标志物。虽然对细胞表面标志物（如PD-L1或HER2）过表达的肿瘤组织进行分析是指导治疗的标准，但组织样本往往难以获取且不足，尤其是在手术后或复发的情况下。新出现的临床证据表明，CTC计数和生物标志物表面表达可以比成像或基于组织的方法更准确地预测预后和治疗耐药性。基于物理特性或表面标记（如EpCAM）的CTC检测方法的最新进展，结合下一代测序（NGS），使这些稀有细胞的分离及其分子特征得以实现。因此，CTC提供了一种实时替代方案，能够重复、纵向评估肿瘤表型和治疗反应。本综述强调了CTC表面蛋白生物标志物（即PD-L1、HER2和EGFR）在分析中的转化潜力，作为一种临床可行的方法，用于对患者进行分层、指导免疫治疗决策和监测最小残留疾病（MRD），特别是在纵向组织活组织检查不可行的情况下。
Abstract
Circulating tumor cells (CTCs) are shed from the primary tumor into the bloodstream and represent dynamic molecular biomarkers for monitoring the progression of cancer. While profiling tumor tissues with over expression of cell surface markers, such as PD-L1 or HER2, is standard in guiding therapy, tissue samples are often inaccessible and inadequate, especially post-surgery or in cases of recurrence. Emerging clinical evidence indicates that CTC counts and biomarker surface expression can predict prognosis and therapeutic resistance more accurately than imaging or tissue-based approaches. Recent advancements in the CTC detection methods, based on physical properties or surface markers (e.g., EpCAM), coupled with next-generation sequencing (NGS) have enabled the isolation of these rare cells and their molecular characterization. Consequently, CTCs provide a real-time alternative, enabling repeated, longitudinal assessment of tumor phenotype and therapeutic response. This review emphasizes the translational potential of surface protein biomarkers on CTCs for profiling, namely PD-L1, HER2, and EGFR, as a clinically actionable approach to stratify patients, guide immunotherapy decisions, and monitor minimal residual disease (MRD), especially when longitudinal tissue biopsies are not feasible.
如何引用
AMA
Saloni Andhari, Jaspreet Farmaha, Ashutosh Vashisht, Vishakha Vashisht, Jana Woodall, Ashis K Mondal, et al. Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells.. Cancers. 2026; doi:10.3390/cancers18030391.
APA
Saloni Andhari, Jaspreet Farmaha, Ashutosh Vashisht, Vishakha Vashisht, Jana Woodall, Ashis K Mondal, et al (2026). Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells.. Cancers. https://doi.org/10.3390/cancers18030391
GB/T 7714
Saloni Andhari, Jaspreet Farmaha, Ashutosh Vashisht, Vishakha Vashisht, Jana Woodall, Ashis K Mondal, et al. Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells.[J]. Cancers, 2026 doi:10.3390/cancers18030391.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出